

Cell Therapy

Part I: Technologies, Ethics & Regulations

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and USA, has held academic positions in several countries, and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is a consultant at Jain PharmaBiotech.

Prof. Jain's 478 publications include 30 books (6 as editor + 24 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the 2017 version is included in a special report on gene therapy published by Jain PharmaBiotech. Other reports written by Prof. Jain have been published by PJB Publications, D & MD, Reuter's Business Insight, and Decision Resources Inc. Cell Therapy is one of the several in-house publications of Jain PharmaBiotech.

Prof. Jain's recent books include "Handbook of Nanomedicine" (1st ed by Springer 2008, Chinese ed by Peking University Press 2011, 2nd edition 2012, 3rd ed 2017 by Springer), "Textbook of Personalized Medicine" (1st ed by Springer 2009; Japanese edition 2012; 2nd ed Springer 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016; 2nd edn Springer 2017), Handbook of Neuroprotection (Springer 2011), Applications of Biotechnology in Cardiovascular Therapeutics (Springer 2011), Applications of Biotechnology in Neurology (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

**November 2018 (first edition published July 2001)
Copyright © 2018 by**

**Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland**

**Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/**

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	26
1. Introduction to Cell Therapy	30
Introduction	30
Historical landmarks of cell therapy	30
Interrelationship of cell therapy technologies	32
Cells and organ transplantation	33
Cells and protein/gene therapy	33
Cell therapy and regenerative medicine.....	34
Cell therapy and tissue engineering.....	35
Therapy based on cells involved in disease.....	35
Advantages of therapeutic use of cells	36
Synthetic cell therapy	36
Cell-based drug delivery	36
<i>Cells as vehicles for gene delivery</i>	<i>37</i>
<i>Red blood cells as vehicles for drug delivery.....</i>	<i>37</i>
<i>Advantages of cell-based drug delivery.....</i>	<i>38</i>
<i>Limitations of cell-based drug delivery.....</i>	<i>39</i>
2. Cell Therapy Technologies	40
Introduction	40
Cell types used for therapy	40
Sources of cells.....	40
Bone marrow.....	40
Blood component therapy	41
<i>Therapeutic apheresis.....</i>	<i>41</i>
<i>Leukoreduction</i>	<i>41</i>
<i>Platelet therapy</i>	<i>42</i>
<i>Red blood cell transfusion</i>	<i>42</i>
Cell lines.....	43
<i>Immortalized cells.....</i>	<i>43</i>
Xenografts	43
Basic technologies for cell therapy	44
Cell culture	44
<i>Automated cell culture devices</i>	<i>44</i>
<i>Cell culture for adoptive cell therapy</i>	<i>44</i>
<i>Observation of stem cell growth and viability.....</i>	<i>44</i>
<i>OpTmizer™ CTS™ T cell expansion tissue culture medium</i>	<i>45</i>
<i>Stem cell movement and behavior in culture.....</i>	<i>45</i>
<i>Companies involved in cell culture.....</i>	<i>45</i>
Cell sorting	47
<i>Flow cytometry.....</i>	<i>47</i>
<i>Applications of flow cytometry</i>	<i>48</i>
<i>A dielectrophoretic system for cell separation.....</i>	<i>48</i>
<i>Adult stem cell sorting by identification of surface markers</i>	<i>48</i>
<i>ALDESORTER system for isolation of stem cells.....</i>	<i>49</i>
<i>Dynabead technology for cell sorting</i>	<i>49</i>
<i>Elutra® Cell Separation System.....</i>	<i>49</i>
<i>Magnetophoretic array-based cell sorting for further studies.....</i>	<i>49</i>
<i>Molecular beacons for specific detection and isolation of stem cells</i>	<i>50</i>
<i>Multitarget magnetic activated cell sorter.....</i>	<i>50</i>
<i>Nanocytometry.....</i>	<i>50</i>
<i>Scepter™ cytometer.....</i>	<i>50</i>
<i>Companies supplying cell sorters</i>	<i>51</i>
Cell analysis.....	52
<i>Cell analyzers.....</i>	<i>52</i>
<i>In vivo cell imaging.....</i>	<i>52</i>
<i>Measuring cell density</i>	<i>53</i>
Single-cell gene expression analysis.....	53
<i>Fluorescent in situ RNA sequencing</i>	<i>54</i>
<i>Single-cell RNA sequencing of stem cells.....</i>	<i>54</i>
Preservation of cells	55
<i>Innovations in cryopreservation.....</i>	<i>55</i>
Packaging of cells	56
Selective expansion of T cells for immunotherapy	57
Cloning and cell therapy	57
Techniques for cell manipulation	58

Altering function of adult human cells	58
Cell-based drug discovery	58
Advantages and limitations of cell-based assays for drug discovery	58
<i>Advantages and limitations of cell-based toxicity screening</i>	<i>59</i>
<i>Quality control of cells for drug discovery</i>	<i>59</i>
Companies involved in cell-based drug discovery	59
Introduction of foreign materials into cells to develop therapeutics	61
Use of cell-penetrating peptides for intracellular transduction	62
Drug delivery systems for cell therapy	62
Intravenous delivery of stem cells	62
Intraarterial delivery of stem cells	63
Pharmacologically active microcarriers	63
Targeted delivery of engineered cells to specific tissues via circulation	63
Devices for delivery of cell therapy	64
Artificial cells	64
Applications of artificial cells	65
Cell encapsulation	65
Cell-in-a-Box®	65
Diffusion capsule for cells	66
Encapsulated cell biodelivery	66
Ferrofluid microcapsules for tracking with MRI	66
Implantation of microencapsulated genetically modified cells	67
Nitric oxide delivery by encapsulated cells	67
Retrievable cell encapsulation device	68
Therapeutic applications of encapsulated cells	68
Companies involved in encapsulated cell technology	69
Electroporation	70
Gene therapy	70
Cell-mediated gene therapy	71
<i>Fibroblasts</i>	<i>71</i>
<i>Chondrocyte</i>	<i>72</i>
<i>Skeletal muscle cells</i>	<i>72</i>
<i>Vascular smooth muscle cells</i>	<i>73</i>
<i>Keratinocytes</i>	<i>73</i>
<i>Hepatocytes</i>	<i>73</i>
<i>Lymphocytes</i>	<i>73</i>
Cell-based CRISPR delivery	73
In vivo tracking of cells	74
Molecular imaging for tracking cells	74
<i>MRI technologies for tracking cells</i>	<i>75</i>
<i>Superparamagnetic iron oxide nanoparticles as MRI contrast agents</i>	<i>76</i>
<i>Survival of labeled hMSCs in regenerative therapy grafts</i>	<i>76</i>
<i>Visualization of gene expression in vivo by MRI</i>	<i>76</i>
Optogenetic monitoring of cell therapies	77
Role of nanobiotechnology in development of cell therapy	77
Nano-biocomposites containing living cells	78
Cell transplantation for development of organs	78
Cells transplantation and tolerance	78
Strategies to improve tolerance of transplanted cells	79
<i>Encapsulation to prevent immune rejection</i>	<i>79</i>
<i>Expansion of allospecific regulatory T cells</i>	<i>79</i>
<i>Prevention of rejection of xenotransplants</i>	<i>79</i>
Removal and replacement of pathogenic cells of the body	80
Therapeutic leukocytapheresis	80
3. Stem Cells	81
Introduction	81
Biology of stem cells	81
Embryonic stem cells	82
Growth and differentiation of ESCs	82
Mechanisms of differentiation of ESCs	83
<i>Chemical regulation of stem cell differentiation</i>	<i>83</i>
<i>In vitro differentiation of hESCs</i>	<i>83</i>
<i>SIRT1 regulation during stem cell differentiation</i>	<i>84</i>
Regulation of stem cell self-renewal and differentiation	84
<i>hESCs for reprogramming human somatic nuclei</i>	<i>84</i>
<i>Stem cells differentiation in the pituitary gland</i>	<i>84</i>
Influence of microenvironment on ESCs	85
Role of genes in differentiation of ESCs	85
<i>Global transcription in pluripotent ESCs</i>	<i>85</i>
<i>Role of p53 tumor suppressor gene in stem cell differentiation</i>	<i>86</i>

<i>Role of Pax3 gene in stem cell differentiation</i>	86
<i>Signaling pathways and ESC genes</i>	86
Epigenetics of hESCs	87
<i>Chromatin as gene regulator for ESC development</i>	87
Mechanism of regulation of stem cells for regeneration of body tissues.....	88
<i>Role of microenvironments in the regulation of stem cells</i>	88
<i>Regulation and regeneration of intestinal stem cells</i>	88
Parthenogenesis and human stem cells.....	89
<i>Uniparental ESCs</i>	89
<i>Haploid ESCs</i>	90
Bone marrow stem cells.....	90
Hematopoietic stem cells	90
<i>Clonal events that regulate HSC development</i>	92
<i>Derivation of HSCs from ESCs</i>	92
<i>Role of HSCs in the immune system</i>	93
Mesenchymal stem cells	93
<i>Cryopreservation of MSCs</i>	95
Multipotent adult progenitor cells	95
Side population stem cells.....	96
Differentiation of adult stem cells.....	96
Growth and differentiation of HSCs	97
<i>HSCs and aging</i>	97
<i>Mathematical modeling of differentiation of HSCs</i>	97
<i>Role of prions in self renewal of HSCs</i>	98
<i>Signaling pathways in the growth and differentiation of HSCs</i>	98
Sources of stem cells	99
Sources of of human embryonic stem cells.....	99
Nuclear transfer to obtain hESCs.....	99
Direct derivation of hESCs from embryos without nuclear transfer	100
Alternative methods of obtaining hESCs.....	100
<i>Establishing hESC lines without destruction of embryo</i>	101
<i>Altered nuclear transfer</i>	102
Advantages and disadvantages of ESCs for transplantation	102
Use of ESC cultures as an alternative source of tissue for transplantation	102
Spermatogonial stem cells	103
Very small embryonic-like stem cells.....	104
Amniotic fluid as a source of stem cells.....	104
<i>Amniotic fluid stem cells for tissue repair and regeneration</i>	104
<i>Generation of iPS cells from AF cells</i>	105
Placenta as source of stem cells.....	105
<i>Amnion-derived multipotent progenitor cells</i>	105
<i>Placenta as a source of HSCs</i>	106
<i>Umbilical cord as a source of MSCs</i>	106
Umbilical cord blood	107
<i>Applications of UCB</i>	107
<i>Advantages of UCB</i>	108
<i>Limitations of the use of UCB and measures to address them</i>	109
<i>Licensing and patent disputes involving UCB</i>	110
<i>Infections following UCB transplants</i>	110
<i>Unanswered questions about UCB transplantation</i>	110
<i>Companies involved in UCB banking</i>	111
<i>UCB banking in the UK</i>	112
<i>US national UCB banking system</i>	113
<i>Future of UCB</i>	113
UCB as source of stem cells.....	114
<i>Cryopreservation of UCB stem cells</i>	114
<i>Epigenetic programming for expansion of UCB cells</i>	115
<i>UCB as source of MSCs</i>	115
Techniques of nuclear reprogramming for stem cells	115
Induced pluripotent stem cells derived from human somatic cells	116
Characteristics of iPSCs	116
DNA methylation patterns of iPSCs	116
Techniques for obtaining iPSCs	117
iPSCs derived from skin	117
iPSCs derived through somatic cell nuclear transfer (SCNT).....	117
<i>iPSCs derived from oocytes</i>	117
<i>iPSCs derived from adult stem cells using SCNT</i>	117
iPSCs derived from blood	118
Use of CRISPR for generation of iPSCs.....	118
Use of retroviral vectors for generation of iPSCs	119
Use of non-integrating viral vectors for generation of iPSCs.....	119

Generation of other cells from iPSCs.....	120
<i>Generation of HSCs from iPSCs</i>	120
<i>Generation of MSCs from iPSCs</i>	120
<i>Generation of RBCs from iPSCs</i>	120
Banks providing patient-specific iPSC lines.....	121
Center for iPS Cell Research Application.....	121
Companies providing iPSCs.....	121
Generation of clinically relevant iPSCs.....	122
<i>Equivalence of human iPSCs and ESCs</i>	123
<i>Genome editing and iPSCs</i>	123
<i>iPSCs and disease modeling</i>	123
<i>iPSCs for patient-specific regenerative medicine</i>	124
<i>Concluding remarks about clinical potential of iPSCs</i>	124
Induced conditional self-renewing progenitor cells.....	125
iXEN cells.....	125
Epiblast stem cells.....	126
Comparison of development of human and mouse ESCs.....	126
Conversion of hESCs to mouse ESC-like naïve states.....	126
Sources of adult human stem cells.....	127
Adipose tissue as a source of stem cells.....	127
<i>Encapsulation and hypothermic storage of adipose-derived stem cells</i>	127
<i>Intravenous infusion of adipose tissue derived MSCs</i>	128
<i>iPSCs derived from adult human adipose stem cells</i>	128
<i>Regulation of adipose stem cells differentiation</i>	128
<i>Transforming adult adipose stem cells into other cells</i>	129
Endometrium as a source of adult stem cells.....	129
Multipotent stem-like cells derived from vascular endothelial cells.....	129
Skin as a source of stem cells.....	129
<i>Controlling the maturation of embryonic skin stem cells</i>	130
<i>Epidermal neural crest stem cells</i>	130
<i>Follicle stem cells</i>	130
<i>Mesenchymal stem cells in skin</i>	131
<i>Regulation of stem cells in hair follicles</i>	131
<i>Skin-derived precursor cells</i>	131
Regulation of epidermal stem cells by circadian rhythms.....	132
Stem cells in teeth.....	132
Peripheral blood stem cells.....	132
Spleen as a source of adult stem cells.....	133
Search for master stem cells.....	133
Vascular cell platform to self-renew adult HSC.....	134
Adult stem cells vs embryonic stem cells.....	134
Biological differences between adult and embryonic stem cells.....	134
Neural crest stem cells from adult hair follicles.....	135
Transdifferentiation potential of adult stem cells.....	135
Attempts at stimulus-triggered acquisition of pluripotency.....	136
Limitations of adult stem cells.....	136
Pitfalls of pluripotency.....	137
Comparison of human stem cells according to derivation.....	137
VENT cells.....	138
ESC banking.....	138
Stem cell technologies.....	138
Analysis of stem cell growth and differentiation.....	138
Activation of bone marrow stem cells into therapeutic cells.....	138
Role of nitric oxide in stem cell mobilization and differentiation.....	139
Role of natriuretic peptide receptor-C in self-renewal of murine ESCs.....	139
Stem cell biomarkers.....	139
<i>Endoglin as a functional biomarker of HSCs</i>	140
<i>STEMPRO® EZChek™ for analysis of biomarkers of hESCs</i>	140
<i>SSEA-4 as biomarker of MSCs</i>	140
<i>p75NTR as a biomarker to isolate adipose tissue-derived stem cells</i>	140
<i>Neural stem cell biomarker</i>	141
<i>Protein expression profile as biomarker of stem cells</i>	141
<i>Real-time PCR for quantification of protein biomarkers</i>	141
Study of stem cell pathways.....	142
Stem cell genomics.....	142
<i>Gene expression in hESCs</i>	142
<i>Genomic alterations in cultured hESCs</i>	143
<i>Study of transcriptional regulation of stem cell genes</i>	143
<i>Casanova gene in zebrafish</i>	143
<i>Nanog gene</i>	143
Gene inactivation to study hESCs.....	145

<i>RNAi to study gene inactivation in hESCs</i>	145
<i>Study of ESC development by inducible RNAi</i>	145
<i>Targeting Induced Local Lesions in Genomes</i>	146
<i>Homologous recombination of ESCs</i>	146
Gene modification in genomes of hESCs and hiPSCs using zinc-finger nuclease.....	146
miRNA and stem cells.....	147
<i>Role of miRNAs in gene regulation during stem cell differentiation</i>	147
<i>Influence of miRNA on stem cell formation and maintenance</i>	147
<i>Restricted differentiation potential of miRNA-deficient PSCs</i>	148
<i>Transcriptional regulators of ESCs control miRNA gene expression</i>	148
Stem cells and cloning.....	148
<i>Cell nuclear replacement and cloning</i>	148
<i>Nuclear transfer and ESCs</i>	148
<i>Cloning from differentiated cells</i>	150
<i>Cloning mice from adult stem cells</i>	150
<i>Creating interspecies stem cells</i>	151
<i>Cloned cells for transplantation medicine</i>	151
<i>Claims of cloning of hESCs</i>	151
<i>hESCs derived by SCNT</i>	153
Cytogenetics of embryonic stem cells.....	153
Stem cell proteomics.....	154
<i>Comparative proteomic analysis of somatic cells, iPSCs and ESCs</i>	154
<i>hESC phosphoproteome</i>	155
<i>Proteomic studies of mesenchymal stem cells</i>	155
<i>Proteomic profiling of neural stem cells</i>	155
<i>Proteome Biology of Stem Cells Initiative</i>	156
Technologies for mobilization, expansion, and engraftment of stem cells.....	156
<i>Chemoattraction of neuronal stem cells through GABA receptor</i>	157
<i>Enhancement of HSC engraftment by calcium-sensing receptor</i>	157
<i>Ex vivo expansion of human HSCs in culture</i>	157
<i>Ex vivo expansion of MSCs</i>	158
<i>Ex vivo expansion of UCB cells for transplantation</i>	158
<i>Expansion of adult stem cells by activation of Oct4</i>	158
<i>Expansion of transduced HSCs in vivo</i>	158
<i>Expansion of stem cells in vivo by Notch receptor ligands</i>	159
<i>In vivo adipogenesis induced by adipose tissue-derived stem cells</i>	159
<i>Selective mobilization of progenitor cells from bone marrow</i>	159
<i>Selective Amplification</i>	160
<i>Synthetic substrates for ESC growth and expansion</i>	160
Technologies for inducing differentiation of stem cells.....	160
<i>Enhancement of stem cell differentiation by Homspera</i>	160
<i>Generation of RBCs from HSCs</i>	161
<i>Generation of multiple types of WBCs from hESCs and iPSCs</i>	161
<i>Growth factor-induced differentiation of MAPCs</i>	161
<i>Lineage selection to induce differentiation of hESCs</i>	161
<i>Mechanical strain to induce MSC differentiation</i>	162
<i>Neurotrophin-mediated survival and differentiation of hESCs</i>	162
<i>Synthetic biology and stem cells</i>	162
<i>Use of RNAi to expand the plasticity of autologous adult stem cells</i>	163
<i>Use of various molecules to induce differentiation of stem cells</i>	163
Limitations of the currently available stem cell lines in the US.....	163
Stem cell separation.....	164
Stem cell culture.....	164
<i>Culture of hMSCs</i>	165
<i>Elimination of contaminating material in stem cell culture</i>	165
<i>Long-term maintenance of MSC multipotency in culture</i>	166
<i>Nanofiber scaffolds for stem cell culture</i>	167
Conversion of stem cells to functioning adipocytes.....	167
Mass production of stem cells.....	168
<i>Mass production of ESCs</i>	168
<i>Mass production of MSCs</i>	168
Promoting survival of dissociated hESCs.....	169
Analysis and characterization of stem cells.....	169
Harvesting and identification of EPCs.....	170
Labeling of stem cells.....	170
Labeling, imaging and tracking of stem cells in vivo.....	170
<i>Perfluorocarbon nanoparticles to track therapeutic cells in vivo</i>	170
<i>PET imaging for tracking of stem cells</i>	171
<i>Project for imaging in stem cell therapy research</i>	171
<i>Quantum dots for labeling and imaging of stem cells</i>	171
<i>Radiolabeling of MSCs for in vivo tracking</i>	172

<i>Superparamagnetic iron oxide nanoparticles for tracking MSCs</i>	172
<i>Tracking of transplanted muscle stem cells</i>	172
Applications of stem cells	172
Commercial development and applications of adult stem cells	173
<i>Preparation of cells for therapeutic administration to patients</i>	173
<i>Retrodifferentiation of stem cells</i>	174
<i>MultiStem</i>	174
Self renewal and proliferation of HSCs	174
Optimizing the preparation and transfer of allogeneic HSCs.....	174
Aging of stem cells.....	175
<i>Aging and rejuvenation of HSCs</i>	175
<i>Aging and MSCs</i>	176
iPSC-based modeling of late-onset age-related diseases	176
Peripheral blood stem cell transplantation	176
Role of stem cells in regeneration	177
<i>Pluripotent stem-cell-derived gastric organoids</i>	177
<i>Promotion of regeneration by Wnt/beta-catenin signaling</i>	177
<i>Stem cell activation for regeneration by using glucocorticoids</i>	178
Stem cells and human reproduction	178
<i>Expansion of spermatogonial stem cells</i>	178
<i>Conversion of ESCs into spermatogonial stem cells</i>	178
<i>Conversion of stem cells to oocytes</i>	179
<i>ESCs for treatment of infertility in women</i>	179
<i>Cloning human embryos from oocytes matured in the laboratory</i>	180
<i>In utero stem cell transplantation</i>	180
Innovations in delivery of stem cells.....	181
<i>Polymeric capsules for stem cell delivery</i>	182
Immunological aspects of hESC transplantation	182
<i>Immunosuppression to prevent rejection of hESC transplants</i>	182
<i>Histocompatibility of hESCs</i>	182
<i>Strategies for promoting immune tolerance of hESCs</i>	183
Stem cells for organ vascularization	183
<i>Activation of EphB4 to enhance angiogenesis by EPCs</i>	184
Advantages and limitations of clinical applications of iPSCs	184
Advantages and limitations of clinical applications of MSCs.....	185
Biofusion by genetically engineering stem cells	185
Stem cell gene therapy.....	185
<i>Combination of gene therapy with nuclear transfer</i>	186
<i>Gene delivery to stem cells by artificial chromosome expression</i>	186
<i>Genetic manipulation of ESCs</i>	186
<i>Genetic engineering of human stem cells for enhancing angiogenesis</i>	187
<i>HSCs for gene therapy</i>	187
<i>iPSCs for targeted gene correction of α1-antitrypsin deficiency</i>	188
<i>Helper-dependent adenoviral vectors for gene transfer in ESCs</i>	188
<i>Lentiviral vectors for in vivo gene transfer to stem cells</i>	188
<i>Linker based sperm-mediated gene transfer technology</i>	188
<i>Mesenchymal stem cells for gene therapy</i>	189
<i>Microporation for transfection of MSCs</i>	189
<i>Regulation of gene expression for SC-based gene therapy</i>	189
<i>Stem cells and in utero gene therapy</i>	189
<i>Therapeutic applications for hematopoietic stem cell gene transfer</i>	190
<i>Targeted genome editing for human repopulating HSCs</i>	190
<i>The future of hematopoietic stem cell gene therapy</i>	190
Stem cell pharmaceuticals	191
Pharmaceutical manipulation of stem cells	191
<i>Expansion of HSCs in culture by inhibiting aldehyde dehydrogenase</i>	192
<i>Expansion of HSCs in vivo by use of prostaglandin E2</i>	192
<i>Manipulation of stem cells with growth factors</i>	192
<i>Mobilization of stem cells by cytokines/chemokines</i>	194
<i>Mobilization of adult human HSCs by use of inhibitors</i>	195
<i>Mobilization of stem cells by HYC750</i>	195
<i>Mobilization of stem cells by hyperbaric oxygen</i>	196
<i>Mobilization by adenoviral vectors expressing angiogenic factors</i>	196
<i>Stem cell mobilization by acetylcholine receptor agonists</i>	196
<i>Use of parathyroid hormone to increase HSC mobilization</i>	197
<i>Use of small molecule compounds for expansion of HSCs</i>	197
<i>Use of a small molecule for targeting systemically infused MSCs</i>	197
Role of stem cells in therapeutic effects of drugs.....	197
Stem cells for drug discovery	198
<i>Target identification</i>	198
<i>High-throughput screening</i>	198

<i>ESCs as source of models for drug discovery</i>	198
<i>hESC-derived hepatocytes for drug discovery</i>	199
<i>hESC-derived cardiomyocytes for drug discovery</i>	199
<i>iPSCs for drug discovery</i>	200
<i>Advantages and limitations of use of stem cells for drug discovery</i>	201
Stem cells for drug delivery	202
Toxicology and drug safety studies using ESCs versus other cells	202
Future challenges for stem cell technologies	204
Generation of patient-specific pluripotent stem cells	204
Hybrid embryos/cybrids for stem cell research	205
In vivo study of human hemopoietic stem cells	206
Inhibition of stem cell-derived teratoma formation by small molecules	206
Markers for characterizing hESC lines	206
MBD3-deficient ESC line	207
Research into plasticity of stem cells from adults	207
Reversion of human stem cells to ground state pluripotency	207
Stem cell biology and cancer	207
Stem cells and aging	208
Stem cells in space	209
Study of the molecular mechanism of cell differentiation	210
Switch of stem-cell function from activators to repressors	210
Stem cell research at academic centers	211
International Regulome Consortium	212
Companies involved in stem cell technologies	212
Concluding remarks about stem cells	217
Challenges and prospects of stem cell research	218
4. Clinical Applications of Cell Therapy	220
Introduction	220
Cell therapy for hematological disorders	220
Transplantation of autologous hematopoietic stem cells	220
Cytomegalovirus infection after allogeneic HSC transplantation	220
<i>Lymphoproliferative disorders after allogeneic HSC transplants</i>	220
HSCs derived from pluripotent stem cells	221
Hemophilias	221
<i>Ex vivo cell/gene therapy of hemophilia B</i>	221
<i>Cell/gene therapy of hemophilia A</i>	222
Hematopoietic stem cell therapy for thrombocytopenia	223
Stem cell transplant for sickle cell anemia	223
Treatment of chronic acquired anemias	223
<i>Implantation of genetically engineered HSCs to deliver rhEpo</i>	224
<i>Drugs acting on stem cells for treatment of anemia</i>	224
Stem cell therapy of hemoglobinopathies	224
<i>iPSC-based therapy for β-thalassemia</i>	225
Stem cells for treatment of immunoglobulin-light chain amyloidosis	225
Future of cell therapy of hematological disorders	225
Cell therapy for immunological disorders	226
Role of dendritic cells in the immune system	226
Modifying immune responses of DCs by vaccination with lipiodol-siRNA mixtures	226
Potential of MSCs as therapy for immune-mediated diseases	227
Stem cell therapy of chronic granulomatous disease	227
Stem cell therapy of X-linked severe combined immunodeficiency	228
Stem cell therapy of autoimmune disorders	228
<i>Wiskott-Aldrich Syndrome</i>	228
<i>Treatment of rheumatoid arthritis with stem cells</i>	228
<i>Treatment of Crohn's disease with stem cells</i>	229
<i>Stem cell transplants for scleroderma</i>	230
Role of T Cells in immunological disorders	230
<i>Autologous T cells from adult stem cells</i>	231
Cell therapy for graft vs host disease	231
<i>T cell infusion for suppressing GVHD</i>	232
<i>Genetically modified Tregs expressing CAR for prevention of GVHD</i>	232
<i>Concluding remarks on prevention and treatment of acute GVHD</i>	233
<i>MSCs for GVHD</i>	233
Cell therapy for viral infections	234
Anti-HIV ribozyme delivered in hematopoietic progenitor cells	234
Dendritic-cell targeted DNA vaccine for HIV	234
Exosomes and viral infections	234
Manipulation of T cells for treatment of viral infections	234
<i>T cell therapy for CMV</i>	234
<i>T cell therapy for HIV infection</i>	235

<i>T cell immunity by Overlapping Peptide-pulsed Autologous Cells</i>	236
Modification of iPSCs with a mutation to confer resistance to HIV	236
Cell therapy of lysosomal storage diseases	236
Niemann-Pick disease.....	237
Gaucher's disease	237
Fabry's disease	238
Cell therapy for endocrine disorders	238
Hypopituitarism	238
Adrenal insufficiency	238
Cell therapy for diabetes mellitus	239
Limitations of current treatment	240
<i>Limitations of insulin therapy for diabetes mellitus</i>	240
<i>Limitations of pancreatic transplantation</i>	240
Islet cell transplantation	240
<i>Autologous pancreatic islet cell transplantation in chronic pancreatitis</i>	241
<i>Clinical trials of pancreatic islet cell transplants for diabetes</i>	241
<i>Drawbacks of islet cell therapy</i>	242
<i>Use of an antioxidant peptide to improve islet cell transplantation</i>	242
<i>Cdk-6 and cyclin D1 enhance human beta cell replication and function</i>	242
<i>Devices for delivery of therapeutic cells in diabetes</i>	243
<i>Monitoring of islet cell transplants with MRI</i>	243
<i>Concluding remarks about allogeneic islet transplantation for diabetes</i>	243
Encapsulation of insulin producing cells	244
<i>Encapsulated porcine pancreatic islet cells for pancreas</i>	244
<i>Encapsulated insulinoma cells</i>	244
<i>Magnetocapsule enables imaging/tracking of islet cell transplants</i>	244
Islet precursor cells.....	245
Dedifferentiation of β cells to promote regeneration	245
Pharmacological approaches for β cell regeneration.....	246
Xenotransplantation of embryonic pancreatic tissue	246
Non-pancreatic tissues for generation of insulin-producing cells	247
Exploiting maternal microchimerism to treat diabetes in the child	247
Bio-artificial substitutes for pancreas.....	247
Role of stem cells in the treatment of diabetes	248
<i>Embryonic stem cells for diabetes</i>	248
<i>HSC transplantation to supplement immunosuppressant therapy</i>	249
<i>Insulin-producing cells derived from UCB stem cells</i>	249
<i>iPSc for diabetes</i>	250
<i>Pancreatic stem cells</i>	250
<i>Pluripotent stem cell-derived pancreatic β-like cells</i>	251
<i>Stem cell injection into portal vein of diabetic patients</i>	251
Conversion of progenitor cells into insulin-producing cells	251
<i>Human neural progenitor cells converted into insulin-producing cells</i>	251
<i>Isolation of islet progenitor cells</i>	251
<i>Pancreatic progenitor cells</i>	252
Cell-based immunotherapy for type 1 diabetes	252
<i>Dendritic cell-based therapy</i>	252
<i>T regulatory cell therapy for diabetes</i>	252
<i>Vaccine for diabetes</i>	253
Synthetic biomimetic β -cells for dynamic insulin secretion.....	253
Gene therapy in diabetes	253
<i>Viral vectors for gene therapy of diabetes</i>	254
<i>Genetically engineered dendritic cells</i>	254
<i>Genetically altered liver cells</i>	254
<i>Genetically modified stem cells</i>	255
Companies developing cell therapy for diabetes.....	255
Concluding remarks about cell and gene therapy of diabetes	256
Cell therapy of gastrointestinal disorders	257
Inflammatory bowel disease.....	257
Cell therapy for liver disorders	257
Types of cells used for hepatic disorders	258
<i>Culture and expansion of primary human hepatocytes</i>	258
<i>Hepatocyte progenitor cells</i>	258
<i>Hybrid periportal hepatocytes</i>	259
Methods of delivery of cells for hepatic disorders	259
Hepatic failure	259
Bioartificial liver.....	260
<i>Hepatocyte-based artificial liver</i>	260
<i>Extracorporeal Liver Assist Device</i>	260
<i>Limitations of bioartificial liver</i>	261
<i>Proliferating cell-based bioartificial liver</i>	261

Stem cells for hepatic disorders	261
<i>Deriving hepatocytes from commercially available hMSCs</i>	262
<i>Implantation of hepatic cells derived from hMSCs of adipose tissue</i>	262
<i>Heterologous adult liver progenitor cells</i>	262
<i>Liver stem cell culture</i>	262
<i>MSC derived molecules for reversing hepatic failure</i>	263
Cell-based gene therapy for liver disorders.....	263
<i>Transplantation of genetically modified fibroblasts</i>	264
<i>Transplantation of genetically modified hepatocytes</i>	264
<i>Genetically modified hematopoietic stem cells</i>	264
<i>iPSCs derived from somatic cells for liver regeneration</i>	264
<i>Hepatocyte-like cells derived from human parthenogenetic stem cells</i>	264
Clinical applications	265
Future prospects of cell-based therapy of hepatic disorders.....	266
Cell therapy of renal disorders.....	266
Bioartificial kidney.....	266
Cell-based repair for vascular access failure in renal disease	267
Mesangial cell therapy for glomerular disease	267
Stem cells for renal disease.....	267
<i>Role of stem cells in renal repair</i>	268
<i>Bone marrow stem cells for renal disease</i>	268
<i>Human amniotic fluid stem cells for renal regeneration</i>	268
<i>MSC therapy for renal disease</i>	269
<i>MSCs as aid to renal graft survival</i>	269
Transplantation of cell-based bioengineered kidney	270
Cell therapy for pulmonary disorders.....	270
Delivery of cell therapy for pulmonary disorders	270
<i>Intratracheal injection of cells for pulmonary hypoplasia</i>	270
Role of stem cells in pulmonary disorders	270
<i>Lung stem cells</i>	270
<i>Lung tissue regeneration from stem cells</i>	271
<i>Role of autologous MSCs in the treatment of severe emphysema</i>	271
<i>Role of stem cells in construction of the Cyberlung</i>	271
<i>Respiratory epithelial cells derived from UCB stem cells</i>	272
<i>Respiratory epithelial cells derived from hESCs</i>	272
<i>Lung tissue engineering with adipose stromal cells</i>	272
<i>Cell-based tissue-engineering of airway</i>	273
Pulmonary disorders that can be treatable with stem cells	274
<i>Acute lung injury and ARDS treated with MSCs</i>	274
<i>Bronchopulmonary dysplasia treated with MSCs</i>	275
<i>Chronic obstructive pulmonary disease treated with MSCs</i>	275
<i>Cystic fibrosis treatment with genetically engineered MSCs</i>	275
<i>Idiopathic pulmonary fibrosis</i>	276
<i>Lung regeneration by integrin $\alpha 6\beta 4$-expressing alveolar epithelial cell</i>	276
<i>Pulmonary arterial hypertension treatment with EPCs</i>	276
Cell therapy for disorders of bones, joints and tendons	277
Cell therapy for repair of fractures and bone defects	277
<i>Bone regeneration by human very small embryonic-like (hVSEL) cells</i>	278
<i>Cell therapy for cervical vertebral interbody fusion</i>	278
<i>Cell-mediated gene therapy for bone regeneration</i>	278
<i>ESCs for bone repair</i>	279
<i>hiPSCs for engineering personalized bone grafts</i>	279
<i>Intrauterine use of MSCs for osteogenesis imperfecta</i>	279
<i>In vivo bone engineering as an alternative to cell transplantation</i>	279
<i>In vivo differentiation of pluripotent stem cells for bone regeneration</i>	279
<i>MSCs for repair of bone defects</i>	280
<i>MSCs for repair of bone fractures</i>	283
<i>Osteocel</i>	283
<i>Stem cells for repairing skull defects</i>	284
<i>Stem cell-based bone tissue engineering</i>	284
<i>Spinal fusion using stem cell-based bone grafts</i>	285
<i>Wnt stimulation to enrich BMSCs for repair of bone fractures</i>	285
Cell therapy of tendon injuries	286
<i>Autologous tenocyte implantation in rotator cuff injury repair</i>	286
<i>Platelet injection for tennis elbow</i>	286
Cell-based techniques for cartilage repair and regeneration.....	287
<i>Cartilage generation from stem cells</i>	287
<i>Cartilage engineering from iPSCs</i>	288
<i>Genetically modified fibroblasts expressing TGF-β for cartilage repair</i>	289
<i>Juvenile cartilage implant for repair of damage to articular cartilage</i>	289
Cell therapy for repair of knee cartilage injuries.....	289

<i>Autologous chondrocyte therapy of the knee</i>	290
<i>Meniscus-derived stem cells</i>	291
<i>MSC-based constructs for knee joint replacement</i>	291
<i>Nanobiotechnology scaffolds for MSC-based cartilage reconstruction</i>	291
<i>Role of cells in the repair of anterior cruciate ligament injury</i>	291
Osteoporosis	292
<i>Stem cell gene therapy for osteoporosis</i>	292
Osteoarthritis of the joints	292
<i>Autologous cultured chondrocytes</i>	293
<i>Autologous intervertebral disc chondrocyte transplantation</i>	294
<i>Intraarticular MSCs for osteoarthritis</i>	295
<i>Mosaicplasty</i>	295
<i>Stem cell therapy of osteoarthritis of the knee</i>	295
Osteonecrosis.....	296
<i>Cell therapy for osteonecrosis</i>	296
<i>Cell therapy for radionecrosis</i>	296
<i>Repair of osteonecrosis by bone marrow derived MSCs</i>	296
Rheumatoid arthritis.....	296
Cell therapy for diseases of the eye	297
Cell therapy for corneal repair	297
Use of human cultured endothelial cells for bullous keratopathy.....	299
Lens regeneration from endogenous stem cells.....	299
Stem cell therapy for limbal stem cell deficiency	299
Role of stem cells in fibrosis following eye injury	300
Stem cell transplantation for radiation sickness	300
MSCs for treatment of radiation damage to the bone.....	300
MSCs for regeneration of ovaries following radiotherapy damage	301
Cell therapy for wound healing	301
Cells to form skin substitutes for healing ulcers	301
CellSpray for wound repair.....	302
Cell therapy for burns.....	303
Closure of incisions with laser guns and cells.....	304
Genetically engineered keratinocytes for wound repair	304
MSCs for wound healing.....	304
Role of amniotic fluid MSCs in repair of fetal wounds	304
Treatment of diabetic foot ulcers with stem cells.....	305
Role of cells in regenerative medicine	305
Stem cells for regeneration of skin and appendages	305
<i>Bifunctional ectodermal stem cells and nail regeneration</i>	305
<i>Stem cells for regeneration of skin in junctional epidermolysis bullosa</i>	305
<i>Follicular stem cells for skin and wound repair</i>	306
<i>Regeneration of aging skin by adipose-derived stem cells</i>	306
<i>Reprogramming autologous stem cells for regeneration of skin</i>	307
<i>Concluding remarks on regeneration of skin by stem cells</i>	307
Cell therapy for regeneration of muscle wasting.....	307
Role of stem cells in regeneration of esophageal epithelium	308
Stem cell-based regenerative therapy for xerostomia	308
Concluding remarks for use of cells in regenerative medicine.....	308
<i>Genomic studies for examining the role of stem cells in regeneration</i>	308
<i>Cell therapy for regenerating organs</i>	309
<i>Umbilical cord blood for regeneration</i>	310
Future prospects of stem cells for regenerative medicine	310
Role of cells in tissue engineering and reconstructive surgery	310
Scaffolds for tissue engineering	310
Improving vascularization of engineered tissues	311
<i>Reconstruction of vasculature</i>	311
Repair of aging skin by injecting autologous fibroblasts	312
Enhancing vascularization by combining cell and gene therapy	312
Nanobiotechnology applied to cells for tissue engineering	312
Choosing cells for tissue engineering	313
Stem cells for tissue repair.....	313
<i>ESCs vs adult SCs for tissue engineering</i>	314
<i>Use of adult MSCs for tissue engineering</i>	314
<i>Measuring MSC interactions with environment for tissue engineering</i>	315
Stem cells for tissue engineering of various organs	315
<i>Breast reconstruction by adipose tissue-derived stem cells</i>	315
<i>Engineering of healthy living teeth from stem cells</i>	316
<i>Intra-uterine repair of congenital defects using amniotic fluid MSCs</i>	317
<i>Skin regeneration by stem cells as an alternative to face transplant</i>	317
<i>Tissue engineering of bone by stem cells</i>	317
Cell-based tissue engineering in genitourinary system	318

<i>Urinary incontinence</i>	318
<i>Tissue engineering of urinary bladder</i>	319
<i>Label retaining urothelial cells for bladder repair</i>	320
<i>MSCs for bladder repair</i>	320
<i>Tissue-engineering of urethra using autologous cells</i>	320
<i>Repair of the pelvic floor with stem cells from the uterus</i>	321
<i>Reconstruction of vagina from stem cells</i>	321
Reconstruction of cartilage for repair of craniofacial defects.....	321
Intraoperative cell therapy	321
Cell therapy for rejuvenation	322
Reversal of muscle weakness and atrophy in aging	322
Reversal of cognitive impairment in aging	323
Treatment of frailty of aging with MSCs	323
Cell therapy for performance enhancement in sports	323
Application of stem cells in veterinary medicine	324
Use of stem cells to repair tendon injuries.....	324
Stem cells for spinal cord injury in dogs.....	324
5. Cell Therapy for Cardiovascular Disorders	325
Introduction to cardiovascular disorders	325
Limitations of current therapies for myocardial ischemic disease	325
Types of cell therapy for cardiovascular disorders	325
Cell-mediated immune modulation for chronic heart disease	327
Inducing the proliferation of cardiomyocytes	327
Pericardial origin of colony-forming units	328
Role of splenic myocytes in repair of the injured heart.....	328
Reprogramming of fibroblasts into functional cardiomyocytes	328
Stem cell-based therapies for cardiovascular diseases	329
<i>Human cardiovascular progenitor cells</i>	329
<i>Human pluripotent stem cell-derived cardiomyocytes</i>	330
<i>Large cardiac-muscle patches based on hiPSC technology</i>	330
<i>Magnetic antibody-linked nanoparticles to deliver cells to the heart</i>	330
<i>Role of the SDF-1-CXCR4 axis in therapies for myocardial ischemia</i>	330
<i>Small molecules to enhance myocardial repair by stem cells</i>	330
<i>Stem cells and atherosclerosis</i>	331
Cell therapy for atherosclerotic coronary artery disease	331
MyoCell™ (Bioheart).....	332
Cardiac stem cells	332
Cardiomyocytes derived from epicardium.....	333
Cardiac atrial appendage stem cells	333
Methods of delivery of cells to the heart	334
Cellular cardiomyoplasty	334
IGF-1 delivery by nanofibers to improve cell therapy for MI.....	334
Non-invasive delivery of cells to the heart by Morph@guide catheter	335
Cell therapy for cardiac revascularization	335
Transplantation of cardiac progenitor cells for revascularization of myocardium	335
Stem cells to prevent restenosis after coronary angioplasty.....	335
Role of cells in cardiac tissue repair	336
Modulation of cardiac macrophages for repair of infarct	336
Transplantation of myoblasts for myocardial infarction.....	336
Patching myocardial infarction with fibroblast culture	337
Cardiac repair with myoendothelial cells from skeletal muscle	337
Myocardial tissue engineering.....	338
Role of stem cells in repair of the heart	339
Role of stem cells in cardiac regeneration following injury	339
Cardiomyocytes derived from adult skin cells	339
Cardiomyocytes derived from ESCs	339
Cardiomyocyte differentiation from hiPSCs	340
Studies to identify subsets of progenitor cells suitable for cardiac repair	341
Technologies for preparation of stem cells for cardiovascular therapy	341
<i>Pravastatin for expansion of endogenous progenitor and stem cells</i>	341
<i>Cytokine preconditioning of human fetal liver CD133+ SCs</i>	342
<i>Expansion of adult cardiac stem cells for transplantation</i>	342
<i>Role of MSCs in growth of CSCs</i>	342
Role of ESCs in repair of the heart	343
<i>ESC transplantation for tumor-free repair of the heart</i>	343
Transplantation of stem cells for myocardial infarction.....	344
<i>Autologous bone marrow-derived stem cell therapeutics</i>	344
<i>Autologous bone marrow-derived mesenchymal precursor stem cells</i>	344
<i>Intracoronary infusion of mobilized peripheral blood stem cells</i>	345
<i>Transplantation of cord blood stem cells</i>	345

<i>Transplantation of hESCs</i>	345
<i>Transplantation of HSCs</i>	346
<i>Transplantation of autologous angiogenic cell precursors</i>	346
<i>Transplantation of adipose-derived stem cells</i>	347
<i>Transplantation of bone marrow-derived cells for myocardial infarct</i>	347
<i>Transplantation of human umbilical cord perivascular cells</i>	348
<i>Transplantation of endothelial cells</i>	349
<i>Transplantation of cardiomyocytes differentiated from hESCs</i>	349
Stem cell therapy for cardiac regeneration	350
<i>3D printed scaffold for regeneration of myocardial infarct with cells</i>	350
<i>Cryopreserved hESC-derived cardiomyocytes for cardiac regeneration</i>	350
<i>Exosomal miRNAs from hiPSC-derived cardiomyocytes</i>	350
<i>HSCs for regeneration of the chronic myocardial infarcts</i>	350
<i>Human MSCs for cardiac regeneration</i>	351
<i>In vivo tracking of MSCs transplanted in the heart</i>	352
<i>MSCs for hibernating myocardium</i>	352
<i>Simultaneous transplantation of MSCs and skeletal myoblasts</i>	352
Transplantation of genetically modified cells	353
Transplantation of genetically modified MSCs	353
Transplantation of cells secreting vascular endothelial growth factor	353
Transplantation of genetically modified bone marrow stem cells.....	353
Cell transplantation for congestive heart failure	353
AngioCell gene therapy for congestive heart failure	354
Injection of adult stem cells for CHF	355
Intracoronary infusion of cardiac stem cells.....	355
Myoblasts for treatment of congestive heart failure	355
Stem cell therapy for dilated cardiac myopathy.....	356
Role of cell therapy in cardiac arrhythmias	356
Biological pacemakers	356
<i>Stem cells as biological pacemakers</i>	357
<i>Stem cells for cardiac arrhythmias</i>	358
Prevention of myoblast-induced arrhythmias by genetic engineering	358
Ventricular tachycardia	358
ESCs for correction of congenital heart defects	359
Cardiac progenitors cells for treatment of heart disease	359
Autologous stem cells for chronic myocardial ischemia	360
Role of cells in cardiovascular tissue engineering	360
Cell-based in vitro regeneration of heart for transplantation	360
Construction of blood vessels with cells	361
<i>Engineered arteries for bypass grafts</i>	361
Engineering heart valves with UCB progenitor cells	362
Epicardial regeneration from hPSCs.....	362
Fetal cardiomyocytes seeding in tissue-engineered cardiac grafts.....	362
Targeted delivery of endothelial progenitor cells labeled with nanoparticles	362
Cell therapy for peripheral vascular disease	363
ALD-301	363
Cell/gene therapy for PVD	363
Cell therapy for CLI in diabetics	363
Colony stimulating factors for enhancing peripheral blood stem cells	363
Intramuscular autologous bone marrow cells.....	364
Ixmyelocel-T cell therapy for critical limb ischemia.....	364
Stem cell-coated vascular grafts for femoral-tibial arterial bypass	365
Clinical trials of cell therapy in cardiovascular disease	365
Mechanism of the benefit of cell therapy for heart disease	368
A critical evaluation of cell therapy for heart disease	368
Publications of clinical trials of cell therapy for CVD	368
Current status of cell therapy for cardiovascular disease	369
Future directions for cell therapy of CVD	369
Combination of cells with biomedical scaffolds	370
Prospects of adult stem cell therapy for repair of heart	370
Role of cells in regeneration of the heart.....	370
Regeneration of cardiomyocytes without use of cardiac stem cells.....	371
6. Cell Therapy for Cancer	372
Introduction	372
Cell therapy technologies for cancer	372
Cell-based delivery of anticancer therapy	373
Cellular immunotherapy for cancer	373
Treatments for cancer by ex vivo mobilization of immune cells	374
Granulocytes as anticancer agents	374
Neutrophil granulocytes in antibody-based immunotherapy of cancer	375

Cancer vaccines	375
Autologous tumor cell vaccines	375
<i>BIOVAXID</i>	375
<i>OncoVAX</i>	376
<i>Tumor cells treated with dinitrophenyl</i>	376
Vaccines that simultaneously target different cancer antigens	376
Gene modified cancer cells vaccines	376
<i>GVAX cancer vaccines</i>	377
<i>K562/GM-CSF</i>	377
Active immunotherapy based on antigen specific to the tumor	377
The use of dendritic cells for cancer vaccination	378
<i>Autologous dendritic cells loaded ex vivo with telomerase mRNA</i>	378
<i>Dendritic cell-targeted protein vaccines</i>	378
<i>Dendritic/tumor cell fusion</i>	378
<i>Electro-hyperthermia for improving DC immunotherapy</i>	379
<i>Genetically modified dendritic cells</i>	379
<i>In vivo manipulation of dendritic cells</i>	379
<i>Preclinical and clinical studies with DC vaccines</i>	380
<i>Vaccines based on dendritic cell-derived exosomes</i>	381
<i>Limitations of DC vaccines for cancer</i>	381
<i>Future developments to enhance clinical efficacy of DC vaccines</i>	381
Cell-based cancer immunotherapy	382
<i>Adoptive cell therapy</i>	382
<i>CD8+ T cells for use in tumor immunotherapy</i>	384
<i>Combination of antiangiogenic agents with ACT</i>	384
<i>Expansion of antigen-specific cytotoxic T lymphocytes</i>	385
<i>Genetically modified T cells for targeting tumors</i>	385
<i>Genetic engineering of tumor cells to activate T helper cells</i>	386
<i>Targeting T regulatory cells</i>	386
<i>T cells with immunological memory and stem cell-like properties</i>	386
<i>T cell imaging for predicting response to cancer vaccines</i>	387
<i>Tumor infiltrating lymphocytes</i>	387
Chimeric antigen receptor T cells	387
<i>Basics of CAR-T cell</i>	387
<i>Basis of anticancer effect of CAR-T cells</i>	387
<i>CAR-T cell manufacture</i>	388
<i>CAR-T cell therapy for leukemia</i>	389
<i>CAR-T cell therapy for multiple myeloma</i>	390
<i>CAR-T cell therapy for lymphoma</i>	390
<i>CAR-T cell therapy for solid tumors</i>	391
<i>Companies developing CAR-T cell therapy</i>	391
<i>CAR NK cells derived from human iPSCs</i>	391
<i>ProCAR-NK cancer immunotherapy</i>	392
<i>Remote control of CAR-T cells</i>	392
<i>Safety of CAR-T cell therapy</i>	392
Chemoimmunotherapy	394
Hybrid cell vaccination	394
Stem cell-based anticancer therapies	394
Stem cell transplantation in cancer	394
<i>Peripheral blood stem cell transplantation</i>	395
<i>Stem cell transplantation for hematological malignancies</i>	397
<i>Long-term results of HSC transplantation</i>	398
<i>Prediction of T cell reconstitution after HSC transplantation</i>	399
<i>HSC transplantation followed by GM-CSF-secreting cell vaccines</i>	399
<i>HSC transplantation for renal cell cancer</i>	399
<i>Umbilical cord blood transplant for hematological malignancies</i>	400
Complications of stem cell transplants in cancer	400
<i>Graft-versus-host disease (GVHD)</i>	400
<i>Delayed immune reconstitution leading to viral infections and relapse</i>	401
<i>Tumor cell contamination</i>	401
<i>Neurological complications</i>	402
<i>Hepatic veno-occlusive disease</i>	402
<i>Current status and safety of allogeneic HSC transplantation</i>	403
<i>Complications of PBSC transplantation in children</i>	403
Role of MSCs in cancer	404
<i>MSC-mediated delivery of anticancer therapeutics</i>	404
<i>Mesenchymal progenitor cells for delivery of oncolytic adenoviruses</i>	404
<i>MSCs for oncolytic HSV delivery for brain metastases of melanoma</i>	404
Nonmyeloablative allogeneic hematopoietic stem cell transplantation	405
hESC-derived NK cells for treatment of cancer	406
ESC vaccine for prevention of lung cancer	406

Genetic modification of stem cells for cancer therapy	406
<i>Genetic modification of hematopoietic stem cells</i>	406
<i>Use of hematopoietic stem cells to deliver suicide genes to tumors</i>	406
<i>Delivery of anticancer agents by genetically engineered MSCs</i>	407
<i>Genetically modified NSCs for treatment of neuroblastoma</i>	407
Innovations in cell-based therapy of cancer	408
Use of immortalized cells	408
Cancer therapy based on natural killer cells.....	408
Cytokine-induced killer cells	409
Mesothelin as a target for cancer immunotherapy	409
Nanomagnets for targeted cell-based cancer gene therapy.....	409
Implantation of genetically modified encapsulated cells for anticancer therapy	409
<i>Antiangiogenesis therapy by implantation of microencapsulated cells</i>	409
<i>Recombinant tumor cells secreting fusion protein</i>	410
<i>A device for filtering cancer and stem cells in the blood</i>	410
Cancer stem cells.....	410
<i>Cancer stem cell biomarkers</i>	411
<i>Integrative nuclear signaling and development of cancer in stem cells</i>	411
<i>Origin of cancer in normal stem cells</i>	411
<i>Role of intestinal stem cells in intestinal polyposis</i>	412
<i>Role of endothelial progenitor cells in tumor angiogenesis</i>	412
<i>Role of cancer stem cells in metastases</i>	412
<i>Role of cancer stem cells in chemotherapy</i>	412
<i>Therapeutic implications of cancer stem cells</i>	413
<i>Targeting breast cancer stem cells</i>	414
<i>Targeting cancer stem cells in leukemia</i>	414
<i>Targeting cancer stem cells in ovarian cancer</i>	415
<i>Targeting cancer stem cells to screen anticancer drugs</i>	415
Companies involved in cell-based cancer therapy.....	415
American Association for Cancer Research and ESCs.....	417
Future of cell-based immunotherapy for cancer.....	417

7. Cell Therapy for Neurological Disorders..... 419

Introduction	419
Use of stem cells for research in neurosciences.....	419
Cerebral organoids for modeling human brain development	419
Use of human stem cell-derived neurons in neuropharmacology	419
Regeneration of brain by in vitro/in vivo reprogramming of cells.....	420
Molecular mechanism of neurogenesis	421
Generation of neurons from astroglia	422
In vivo cell replacement therapy by locally induced neural progenitor cells.....	422
In vivo reprogramming to generate new neurons.....	422
Types of cells used for treatment of neurological disorders.....	423
Activated T lymphocytes	424
Differentiation of placenta-derived multipotent cells into neurons.....	424
Fibroblast-derived human striatal neurons	424
Mesenchymal stem cells induced to secrete neurotrophic factors.....	424
MUSE cells transplantation for neuronal regeneration	425
Neural stem cells	425
<i>Development of human CNS stem cells</i>	425
<i>Direct conversion of adult fibroblasts into neural progenitor cells</i>	426
<i>Distinction between NSCs and intermediate neural progenitors</i>	426
<i>Embryonic stem cell-derived neurogenesis</i>	426
<i>Epidermal neural crest stem cells for neurological disorders</i>	427
<i>Fusion of NSCs with endogenous neurons</i>	427
<i>Induction of NSCs from hESCs</i>	427
<i>Induction of NSCs from adult MSCs</i>	428
<i>Mechanism of migration of NSCs to sites of CNS injury</i>	428
<i>Monitoring of implanted NSCs labeled with nanoparticles</i>	429
<i>Neural progenitor cells</i>	429
<i>Neural stem cells in the subventricular zone of the brain</i>	431
<i>Oligodendrocyte progenitor cells</i>	431
<i>Promotion of neural stem cells expansion by betacellulin</i>	431
<i>Proteomics of neural stem cells</i>	431
<i>Regulation of neural stem cells in the brain</i>	432
<i>Role of CSF in regulation of neural progenitor cells</i>	433
<i>Sequencing the transcriptomes of neural stem cells</i>	433
<i>Study of neural differentiation of hESCs by NeuroStem Chip</i>	434
<i>Transformation of neural stem cells into other cell types</i>	434
Stem cell transplantation in the CNS	434
<i>Development of CNS cells from non-CNS stem cells</i>	434

<i>Expansion of adult human neural progenitors</i>	435
<i>Hair-follicle stem cells for neural repair</i>	435
<i>Human NSCs for treatment of neurological disorders</i>	436
<i>NSCs and scaffolds for regeneration therapy of CNS disorders</i>	436
<i>Neurospheres</i>	437
<i>Stem cells from olfactory epithelium for transplantation in the CNS</i>	437
<i>Stem cells from human umbilical cord blood for CNS disorders</i>	437
Choroid plexus cells for transplantation	438
Dental pulp cells for neuroprotection	438
Derivation of CNS cells from peripheral nervous system	438
Fetal tissue transplants	439
Immortalized cells for CNS disorders	439
Laboratory mice with human brain cells	440
Olfactory ensheathing cells for CNS repair	440
Ideal cells for transplantation into the nervous system	440
Cell therapy techniques for neurological applications	441
Carbon nanotubes to aid stem cell therapy of neurological disorders	441
Cell transplantation for regeneration of the nervous system	441
Cells used for gene therapy of neurological disorders	441
<i>Fibroblasts</i>	442
<i>Stem cells</i>	442
<i>Neuronal cells</i>	442
<i>Immortalized neural progenitor cells</i>	442
<i>Astrocytes</i>	443
<i>Cerebral endothelial cells</i>	443
<i>Human retinal pigmented epithelial cells</i>	443
Enhancement of growth of stem cells in the brain by drugs	444
<i>C3-induced differentiation and migration of NPC for repair of the brain</i>	444
Stem cell therapies of neurological disorders combined with HBO	445
hESCs for CNS repair	445
Motor neurons derived from stem cells	445
MSCs for CNS repair	446
Neuronal differentiation of stem cells	447
<i>Apigenin promotes differentiation of stem cells into neural lineage</i>	447
Stem cells preparations for CNS disorders	447
Tracking of stem cells in the CNS by nanoparticles and MRI	448
Use of neural stem cells to construct the blood brain barrier	449
Methods of delivery of cells to the CNS	449
<i>Cerebrospinal fluid-stem cell interactions for therapy of CNS disorders</i>	449
<i>CNS delivery of cells by catheters</i>	450
<i>Engineered stem cells for drug delivery to the brain</i>	450
<i>Encapsulated cells</i>	450
<i>Intrathecal delivery of stem cells</i>	450
<i>Intraparenchymal delivery of stem cells to the spinal cord</i>	451
<i>Intravascular administration</i>	451
<i>Neural stem cells as therapeutic delivery vehicles</i>	452
Neurological disorders amenable to cell therapy	452
Neuroprotection by cell therapy	453
<i>Cells secreting neuroprotective substances</i>	453
<i>Stem cells for neuroprotection</i>	453
<i>Neuroprotection by intravenous administration of HSCs</i>	453
<i>Human UCB-derived stem cells for the aging brain</i>	453
Neurodegenerative disorders	454
<i>MSCs for therapy of neurodegenerative disorders</i>	454
<i>Role of stem cells in neurodegenerative disorders</i>	455
<i>Role of NSCs in disorders associated with aging brain</i>	455
<i>NSCs for improving memory</i>	456
Parkinson's disease	456
<i>Cell therapies for PD</i>	457
<i>Delivery of cells for PD</i>	458
<i>Dopamine neurons for PD</i>	458
<i>Encapsulated cells for PD</i>	459
<i>Graft survival-enhancing drugs</i>	459
<i>Human retinal pigment epithelium cells for PD</i>	460
<i>Potential of regeneration of endogenous stem cells in PD</i>	460
<i>Pluripotent stem cell-derived neurons</i>	461
<i>Stem cell transplantation in animal models of PD</i>	461
<i>Stem cells for production of glial derived neurotrophic factor</i>	463
<i>Transplantation of embryonic medial ganglionic eminence cells</i>	463
<i>Trials of stem cell transplantation in PD patients</i>	464
<i>Tumorigenic potential of transplanted dopaminergic hESCs</i>	465

<i>Xenografting porcine fetal neurons</i>	465
<i>Personalized stem cell therapy for PD</i>	466
<i>Future perspectives of clinical trials of stem cell therapy for PD</i>	467
MSCs for multiple system atrophy	467
Cell therapy for Huntington's disease.....	468
<i>Fetal striatal cell transplantation</i>	468
<i>Transplantation of encapsulated porcine choroids plexus cells</i>	468
<i>iPSCs for HD</i>	468
<i>Mobilization of endogenous neural progenitor cells in HD</i>	469
Cell therapy for Alzheimer's disease	469
<i>Choroid plexus epithelial cells for AD</i>	469
<i>Implantation of genetically engineered cells producing NGF</i>	470
<i>Neural stem cell implantation for Alzheimer's disease</i>	470
<i>Use of autologous stem cells for dementia</i>	471
Cell therapy for amyotrophic lateral sclerosis.....	471
<i>Stem cell techniques for study of ALS</i>	471
<i>Rational for use of stem cells for ALS</i>	471
<i>Experimental studies with various types of stem cells for ALS</i>	472
<i>Clinical trials of stem cells for ALS</i>	473
<i>Transplantation of glial restricted precursors in ALS</i>	474
<i>Stem cell-based drug discovery for ALS</i>	475
Cell therapy for demyelinating disorders	475
<i>Autologous bone marrow stem cell therapy for multiple sclerosis</i>	476
<i>ESCs for remyelination</i>	476
<i>Fusokine method of personalized cell therapy of MS</i>	476
<i>Genetically engineered macrophages expressing Nav1.5</i>	476
<i>Hematopoietic stem cell transplantation for MS</i>	477
<i>MSCs for multiple sclerosis</i>	477
<i>Neural progenitor cells for neuroprotection in MS</i>	478
<i>NSC transplantation for repair of demyelination after</i>	478
<i>iNSCs for antiinflammatory effect in MS</i>	479
<i>Oligodendrocyte generation from human iPSCs</i>	479
<i>T cell-based personalized vaccine for MS</i>	479
<i>T cell-directed therapies for MS</i>	479
<i>Stem cells for chronic inflammatory demyelinating polyneuropathy</i>	479
<i>Stem cell transplantation for Pelizaeus-Merzbacher disease</i>	480
<i>X-linked adrenoleukodystrophy</i>	480
Cell therapy of stroke	480
<i>Adult stem cell therapy in stroke</i>	481
<i>Cell therapy of intracerebral hemorrhage</i>	482
<i>Implantation of genetically programmed ESCs</i>	482
<i>Intravenous infusion of MSCs</i>	483
<i>Intravenous infusion of human UCB stem cells</i>	483
<i>Intravenous MSCs to prevent rupture of experimental aneurysms</i>	484
<i>Intracerebral administration of human adipose tissue stromal cells</i>	484
<i>Neural stem cell therapy for stroke</i>	484
<i>Transplantation of encapsulated porcine choroids plexus</i>	485
<i>Transplantation of fetal porcine cells</i>	486
<i>Role of cell therapy in management of stroke according to stage</i>	486
<i>Clinical trials of cell therapy for stroke</i>	486
<i>Future of cell therapy for stroke</i>	488
Cell therapy of traumatic brain injury	489
<i>Cell/gene therapy for TBI</i>	489
<i>Clinical trials of autologous stem cell therapy for TBI</i>	489
<i>Limitations of stem cell therapy for acute TBI</i>	490
<i>Improving the microenvironments of transplanted cells in TBI</i>	490
<i>MSC-derived exosomes for treatment of TBI</i>	491
Cell therapy for spinal cord injury	491
<i>Autoimmune T cells against CNS myelin-associated peptide</i>	491
<i>Fetal neural grafts for SCI</i>	492
<i>Olfactory-ensheathing cells for SCI</i>	492
<i>Oligodendrocyte precursor cells for treatment of SCI</i>	492
<i>Schwann cell transplants for SCI</i>	493
<i>Transplantation of glial cells for SCI</i>	493
Stem cells for SCI	493
<i>Bone marrow stem cells for SCI</i>	493
<i>Embryonic stem cells for SCI</i>	493
<i>ESC-derived neural aggregates for treatment of SCI</i>	494
<i>Transplantation of induced pluripotent stem cells in SCI</i>	495
<i>Transplantation of MSCs for SCI</i>	495
<i>Transplantation of NSCs for SCI</i>	495

<i>Transplantation of human dental pulp stem cells</i>	496
<i>Transdifferentiation of BM stem cells into cholinergic neurons for SCI</i>	496
<i>Evaluation of experimental studies of stem cell transplantation in SCI</i>	497
Spinal stem cells for treatment of ischemic injury of spinal cord.....	497
Combined approaches for regeneration in SCI.....	497
<i>Combined cell/gene therapy for SCI</i>	498
Delivery of cells in SCI.....	498
<i>Intrathecal injection of cells labeled with magnetic nanoparticles</i>	498
<i>Intravenous injection of stem cells for spinal cord repair</i>	499
Clinical applications of stem cells for SCI.....	499
<i>Autologous bone marrow cell transplantation for SCI</i>	499
<i>Cell therapy of syringomyelia</i>	499
Cell therapy for neurogenetic disorders.....	500
<i>Hurler's syndrome treated with stem cells</i>	500
<i>Krabbe's disease treated with UCB stem cells</i>	501
<i>Krabbe's disease treated with combination of cell and gene therapy</i>	501
<i>Mitochondrial encephalomyopathies treated with stem cells</i>	501
<i>Sanfilippo syndrome type B treated with UCB stem cells</i>	502
Cell therapy for lysosomal storage disorders.....	502
<i>Cell therapy for Batten disease</i>	502
<i>Cell/gene therapy for Farber's disease</i>	503
<i>Genetically modified HSCs for metachromatic leukodystrophy</i>	503
<i>Neural stem cells for lysosomal storage disorders</i>	503
Cell therapy of epilepsy.....	504
<i>Cell therapy of posttraumatic epilepsy</i>	504
<i>Cell therapy for temporal lobe epilepsy</i>	504
<i>Cell therapy for pharmaco-resistant epilepsies</i>	505
Cell therapy for developmental neurological disorders.....	505
Cell therapy for cerebral palsy.....	505
Cell-based therapies for malignant CNS tumors.....	506
<i>Bone morphogenetic protein for inhibition of glioblastoma multiforme</i>	506
<i>Dendritic cell therapy for brain tumors</i>	507
<i>Encapsulated cells for brain tumors</i>	507
<i>Engineered human NSCs for treatment of spinal cord gliomas</i>	508
<i>Immunotherapy of GBM targeting cancer stem cells</i>	508
<i>Mesenchymal stem cells for the treatment of gliomas</i>	508
<i>Neural stem cells for treatment of malignant brain tumors</i>	509
<i>Role of cancer stem cells in resistance to radiotherapy</i>	510
<i>Stem cell-based therapy targeting EGFR in GBM</i>	511
<i>Targeting stem cells in brain tumors</i>	511
<i>Clinical trials of cell therapy of glioblastoma multiforme</i>	511
Cell therapy for chemobrain.....	511
Cell therapy for muscle disorders.....	512
<i>Duchenne muscular dystrophy</i>	512
<i>Combination of cell and pharmacotherapy for DMD</i>	513
<i>Myoblast transplant for DMD</i>	513
<i>Myoblast-based gene transfer</i>	513
<i>Myoblasts lacking the MyoD gene</i>	514
<i>Myoblast injection for treatment of other muscular dystrophies</i>	514
<i>Role of satellite cells in the treatment of DMD</i>	514
<i>Stem cells for DMD</i>	515
<i>Wnt7a treatment for DMD</i>	516
Cell therapy for autism.....	517
Management of chronic intractable pain by cell therapy.....	517
<i>Implantation of chromaffin cells</i>	517
<i>Role of stem cells in management of pain</i>	518
<i>Implantation of astrocytes secreting enkephalin</i>	518
<i>Cells for delivery of antinociceptive molecules</i>	518
<i>Implantation of genetically engineered cells</i>	519
<i>Cell therapy for low back pain</i>	519
Cell therapy for neuropathic itch.....	519
Cell therapy for neuroendocrine disorders.....	520
<i>Pituitary stem cells</i>	520
Cell therapy for regenerating optic pathways.....	520
Cell therapy for retinal degenerative disorders.....	521
<i>Delivery of CNTF by encapsulated cell intraocular implants</i>	521
<i>Genetically engineered retinal pigmented epithelial cell lines</i>	521
Stem cell-based therapies for retinal degenerative disorders.....	522
<i>Adipose-derived stem cells for retinal degeneration</i>	522
<i>Adipose-derived stem cells transplantation for diabetic retinopathy</i>	522
<i>ESCs for retinal degenerative disorders</i>	522

<i>hESC-derived RPE cells for AMD</i>	523
<i>Human retinal stem cells</i>	523
<i>iPSCs for AMD</i>	524
<i>Neuroprotective effect of neural progenitor cell transplantation</i>	525
<i>Stem-cell based therapy for retinitis pigmentosa</i>	525
<i>Stem cell transplantation in the retina</i>	525
<i>Combining stem cell and gene therapies for retinal disorders</i>	526
Clinical trials of cell therapy for retinal degenerative disorders	526
Stem cell therapy for hearing loss	527
Cell therapy for peripheral nerve lesions.....	528
<i>Cell transplants for peripheral nerve injuries</i>	528
<i>Role of adipose-derived stem cells in peripheral nerve regeneration</i>	528
<i>Treatment of diabetic neuropathy with endothelial progenitor cells</i>	528
Complications of cell therapy of neurological disorders	529
Tumor formation after CNS transplantation of stem cells.....	529
<i>Donor stem cell-derived brain tumor</i>	529
<i>Glioproliferative lesion of spinal cord as a complication of cell therapy</i>	529
<i>Uncontrolled differentiation of implanted ESCs</i>	529
Tumorigenicity of ESC-derived retinal progenitor cells	530
Clinical trials of cell therapy in neurological disorders	530
Future of cell therapy of CNS disorders	531

8. Ethical, Legal and Political Aspects of Cell therapy 533

Introduction	533
Political and ethical aspects of hESC research in the US	533
Ethical issues concerning fetal tissues.....	533
<i>Morality and hESC research</i>	534
Opponents of hESC research in the US	534
<i>Use of hESCs in NIH-supported research</i>	535
<i>Politics of hESC research in the US</i>	536
<i>Public opinion in the US about hESC research</i>	538
<i>Human stem cell cloning in the US</i>	539
<i>Stem cell guidelines of various US institutions</i>	540
Ethics of transplanting human NSCs into the brains of nonhuman primates	541
Stem cell research around the world	541
ESC lines available worldwide	542
ESC policies around the world	543
Countries with no defined policies on hESC research	544
Australia	544
Canada.....	545
China	545
Denmark	546
France.....	546
Germany	547
India	548
Ireland	549
Israel	549
Italy.....	550
Japan	550
Russia	551
The Netherlands	551
Saudi Arabia.....	551
Singapore	551
South Africa	552
South Korea.....	552
Spain	552
Sweden	553
Switzerland	553
United Kingdom	554
<i>UK StemCellBank</i>	554
European Union	555
<i>EU guidelines for stem cell research</i>	555
<i>European stem cell bank</i>	557
<i>EMBO's recommendations for stem cell research</i>	557
Public opinion in Europe about hESC research.....	558
United Nations, cloning and nuclear transfer.....	559
The Embryo Project for information on ESC research	559
Concluding remarks about ethics of ESC research	559
Ethical issues concerning umbilical cord blood	560
Legal issues associated with stem cells	560
Stem cell patents	560

Stem cell patents in the United States	560
Current status of Thomson patents at WARF.....	561
Stem cell patents in the European Union.....	561
Cell therapy tourism	562

9. Safety and Regulatory Aspects of Cell Therapy	564
Introduction	564
Safety issues of cell therapy	564
Immune-mediated reactions to transplanted stem cells	564
Human virus infections associated with stem cell transplantation	565
<i>Herpes simplex virus type 1</i>	565
<i>Cytomegalovirus</i>	565
Opportunistic infections among hematopoietic stem cell transplant recipients	565
Cord colitis syndrome	565
Carcinogenic potential of stem cells and its prevention	566
Regulatory challenges for the clinical use of cell products.....	566
Prediction of in vivo performance of cell-based therapies	566
FDA safety regulations for cell and tissue products	567
FDA Guidance on license applications for umbilical cord blood products.....	568
Regulation of cord blood banks in the US	568
Regulatory issues for biotechnology-derived drugs	568
Regulation of products for adoptive cell therapy of cancer	569
Regulation of cell selection devices for PBSCs at point of care	569
FDA rules for human cells and tissues	570
FDA regulation of fetal cellular or tissue products.....	570
<i>FDA and ESC lines</i>	571
FDA and clinical trials using hESCs	571
Cell and gene therapies approved by the FDA.....	572
Cell and gene therapy INDs placed on hold by the FDA	572
Regulatory issues for genetically engineered cell transplants	573
FDA guidelines for human tissue transplantation	573
FDA considers cultured stem cells for therapy as drugs.....	573
FDA perspective on safety-efficacy and risk-benefit of stem cell therapy	573
FDA action against unapproved cell therapy in the US	576
Xenotransplantation	577
Clinical Protocol Review and Oversight.....	577
Informed consent and patient education	577
Xenotransplantation product sources	578
FDA guidelines for xenografts.....	578
US regulations for manufacture of cell therapy products	580
<i>GMP in USA</i>	581
Regulations relevant to cell therapy in the European Union.....	581
Regulations about use of stem cells in the EU	583
Guidelines for cell therapy in the UK.....	583
Quality requirements for ex vivo-expanded MSC products for clinical use	583
European regulations for manufacture of cell therapy products	584
<i>GMP in Europe</i>	584
Global regulation of stem cell approval.....	584
Transport of stem cells between countries	585
Temperature limitations during transport of stem cells	585
NIH and stem cells.....	585
hESC lines approved under the new NIH guidelines	585
Clinical trials in cell therapy.....	586
Assessment of clinical trial registration and publication	586
Misuse of listing on ClinicalTrials.gov to provide unapproved stem cell therapy	587

Tables

Table 1-1: Landmarks in the history of cell therapy	30
Table 1-2: Examples of cells involved in various diseases	35
Table 2-1: Types of human cells used in cell therapy.....	40
Table 2-2: A selection of companies providing cell culture media	45
Table 2-3: A sampling of companies supplying cell sorters	51
Table 2-4: Companies involved in cell-based drug discovery	60
Table 2-5: Methods of delivery of cells for therapeutic purposes	62
Table 2-6: Therapeutic applications of encapsulated cells.....	68
Table 2-7: Companies working on encapsulated cell technology.....	69
Table 2-8: Molecular imaging methods for tracking cells in vivo.....	75
Table 3-1: Various levels of potency relevant to stem cells	82
Table 3-2: Clinical trials of UCB	108
Table 3-3: Companies involved in cord blood banking as a source of stem cells	111
Table 3-4: Comparison of techniques for nuclear reprogramming of stem cells	115

Table 3-5: Banks of patient-specific iPSC lines.....	121
Table 3-6: Companies providing iPSCs	121
Table 3-7: Sources of adult human stem cells	127
Table 3-8: Comparison of human stem cells according to derivation.....	137
Table 3-9: Enhancing engraftment, mobilization and expansion of stem cells	156
Table 3-10: Applications of stem cells	173
Table 3-11: Advantages and limitations of methods for optimizing MSCs	185
Table 3-12: Pharmaceutical manipulation of stem cells.....	191
Table 3-13: Growth factors with positive effects on stem cells and applications	192
Table 3-14: Examples of drugs that induce granulocytopenia at stem cell level.....	203
Table 3-15: Academic institutes involved in stem cell research	211
Table 3-16: Companies involved in stem cell technologies	212
Table 4-1: Therapeutic applications of regulatory T cells (Tregs).....	231
Table 4-2: Various tissue/cell therapy approaches to the treatment of type 1 diabetes	239
Table 4-3: Companies involved in cell therapy for insulin-dependent diabetes	255
Table 4-4: Major pulmonary disorders potentially treatable by stem cell manipulation	274
Table 4-5: Cell-based repair of knee cartilage damage	290
Table 4-6: Intraoperative cell therapy	322
Table 5-1: Classification of various types of cell therapy for cardiovascular disorders	326
Table 5-2: Clinical trials of cell therapy in cardiovascular disease.....	365
Table 6-1: Cell therapy technologies used for cancer.....	372
Table 6-2: Companies involved in developing cell-based therapies for cancer	416
Table 7-1: Studies in rats or mice of in vivo reprogramming of cells for brain repair.....	423
Table 7-2: NSCs-based approaches for neurological disorders.	436
Table 7-3: Experimental use of immortalized cells for CNS disorders	439
Table 7-4: Combination of stem cells and HBO in models of neurological disorders	445
Table 7-5: Therapeutic applications of MSCs for neurological disorders.....	446
Table 7-6: Methods for delivering cell therapies in CNS disorders.....	449
Table 7-7: Neurological disorders amenable to cell therapy.....	452
Table 7-8: Types of cell used for investigative treatment of Parkinson's disease	457
Table 7-9: Status of cell therapies for Parkinson's disease	457
Table 7-10: Role of cell therapy in management of stroke according to stage.....	486
Table 7-11: Clinical trials of cell therapy for stroke: completed, ongoing and pending	486
Table 7-12: Clinical trials of cell therapy for retinal degenerative disorders	526
Table 7-13: Clinical trials with cell therapy in neurological disorders (excluding stroke)	530
Table 8-1: Listed numbers of ESC lines around the world.....	542
Table 8-2: Stem cell policies around the world	543
Table 8-3: European public attitudes about research involving human stem cells	558
Table 9-1: Possible adverse reactions and safety issues of cell therapy.....	564
Table 9-2: Cell and gene therapies approved by the FDA	572

Figures

Figure 1-1: Interrelationships of cell therapy to other technologies	33
Figure 1-2: Interrelationships of gene, cell and protein therapies.....	34
Figure 1-3: Engineering of RBCs for drug delivery.....	38
Figure 3-1: A simplified biological scheme of embryonic stem Cells	82
Figure 3-2: Steps of iPS cell production	116
Figure 3-3: hESC-derived by somatic cell nuclear transfer	153
Figure 3-4: Approaches for optimizing preparation of HSCs for transplantation	175
Figure 3-5: Flow chart of development of stem cells with potential bottlenecks.....	218
Figure 4-1: Reprogramming ESCs/iPSCs cells to β -cells for type 1 diabetes	250
Figure 4-2: Fluorescently labeled polarized Upcyte® hepatocytes	258
Figure 5-1: Ex vivo vs in vivo approaches to regeneration of the heart	326
Figure 5-2: hESC-derived cardiomyocytes from laboratory to bedside	340
Figure 5-3: Steps in growing a new heart in vitro for transplantation.....	361
Figure 6-1: A scheme of generation and administration of tumor antigen-pulsed dendritic cells	381
Figure 6-2: Chimeric antigen receptor (CAR)-T cells attacking tumor cells.....	388
Figure 6-3: Stem cell transplantation techniques	396
Figure 7-1: Cell-based methods for repair of the brain.....	420
Figure 7-2: Reprogramming methods for in vivo generation of neurons.	421
Figure 7-3: Stem cells that can give rise to neurons.....	430
Figure 7-4: Sources of dopaminergic neurons for transplantation in Parkinson's disease	458
Figure 7-5: Scheme of iPSCs for personalized cell therapy of Parkinson disease.....	467
Figure 7-6: Potential mechanisms of stem cell efficacy in ALS	472
Figure 7-7: Approaches to stem cell therapy in stroke	482
Figure 8-1: Global stem cell research publications 2013-2017	542